COVID‐19 immunopathology with emphasis on Th17 response and cell‐based immunomodulation therapy: potential targets and challenges

A Pourgholaminejad… - Scandinavian Journal …, 2022 - Wiley Online Library
The role of the immune system against coronavirus disease 2019 (COVID‐19) is unknown in
many aspects, and the protective or pathologic mechanisms of the immune response are …

Inflammatory cytokine: IL-17A signaling pathway in patients present with COVID-19 and current treatment strategy

T Shibabaw - Journal of inflammation research, 2020 - Taylor & Francis
Abstract Coronavirus disease 2019 (COVID-19) is a globally communicable public health
disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV-2) …

[HTML][HTML] Effect of antiviral and immunomodulatory treatment on a cytokine profile in patients with COVID-19

D Martonik, A Parfieniuk-Kowerda, A Starosz… - Frontiers in …, 2023 - frontiersin.org
Background The severity of COVID-19 is associated with an elevated level of a variety of
inflammatory mediators. Increasing evidence suggests that the Th17 response contributes to …

Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions

Y Jamilloux, T Henry, A Belot, S Viel, M Fauter… - Autoimmunity …, 2020 - Elsevier
The coronavirus disease-19 pandemic (COVID-19), which appeared in China in December
2019 and rapidly spread throughout the world, has forced clinicians and scientists to take up …

T cell immunobiology and cytokine storm of COVID‐19

XH Luo, Y Zhu, J Mao, RC Du - Scandinavian journal of …, 2021 - Wiley Online Library
Abstract 2019 coronavirus disease (COVID‐19) presents as a newly recognized pneumonia
and could rapidly progress into acute respiratory distress syndrome which has brought …

The role of Th17 response in COVID-19

D Martonik, A Parfieniuk-Kowerda, M Rogalska… - Cells, 2021 - mdpi.com
COVID-19 is an acute infectious disease of the respiratory system caused by infection with
the SARS-CoV-2 virus (Severe Acute Respiratory Syndrome Coronavirus 2). Transmission …

T‐cell responses and therapies against SARS‐CoV‐2 infection

SM Toor, R Saleh, V Sasidharan Nair, RZ Taha… - …, 2021 - Wiley Online Library
Abstract Coronavirus disease 2019 (COVID‐19) is caused by SARS‐CoV‐2, a novel
coronavirus strain. Some studies suggest that COVID‐19 could be an immune‐related …

A case for targeting Th17 cells and IL-17A in SARS-CoV-2 infections

M Orlov, PL Wander, ED Morrell… - The Journal of …, 2020 - journals.aai.org
Abstract SARS-CoV-2, the virus causing COVID-19, has infected millions and has caused
hundreds of thousands of fatalities. Risk factors for critical illness from SARS-CoV-2 infection …

Cellular and humoral immune responses in covid-19 and immunotherapeutic approaches

A Hasan, E Al-Ozairi, Z Al-Baqsumi… - ImmunoTargets and …, 2021 - Taylor & Francis
Abstract Coronavirus disease 2019 (Covid-19), caused by the novel coronavirus severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can range in severity from …

[HTML][HTML] Immunomodulation for severe COVID-19 pneumonia: the state of the art

Y Zhang, Y Chen, Z Meng - Frontiers in immunology, 2020 - frontiersin.org
COVID-19 has become a worldwide pandemic caused by the novel coronavirus named
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Severe cases of COVID-19 …